Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Ebrecht, M.
Sickmann, V
Kungel, M.
Werner, C.
Marcus, R.
McQuade, R.
Modell, S.
机构：
[1] Bristol Myers Squibb Co, Munich, Germany
[2] Otsuka Pharma GmbH, Frankfurt, Germany
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[4] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
来源：
PHARMACOPSYCHIATRY | 2007年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：207 / 207
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial
    Farajollahi-Moghadam, Mostafa
    Sanjari-Moghaddam, Hossein
    Hasemi, Maryam Ghazizadeh
    Sanatian, Zahra
    Talaei, Ali
    Akhondzadeh, Shahin
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (03) : 140 - 146
  • [22] The Efficacy and Safety of Basimglurant as Adjunctive Therapy in Major Depression; a Randomized, Double-blind, Placebo Controlled Study
    Quiroz, Jorge
    Tamburri, Paul
    Deptula, Dennis
    Banken, Ludger
    Beyer, Ulrich
    Fontoura, Paulo
    Santarelli, Luca
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S376 - S377
  • [23] Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)
    Kamijima, Kunitoshi
    Higuchi, Teruhiko
    Ishigooka, Jun
    Ohmori, Tetsuro
    Ozaki, Norio
    Kanba, Shigenobu
    Kinoshita, Toshihiko
    Koyama, Tsukasa
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (03) : 899 - 905
  • [24] Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
    Inoue, Takeshi
    Sasai, Kiyofumi
    Kitagawa, Tadayuki
    Nishimura, Akira
    Inada, Isao
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (02) : 140 - 148
  • [25] A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder
    Mahableshwarkar, Atul R.
    Jacobsen, Paula L.
    Serenko, Michael
    Chen, Yinzhong
    Trivedi, Madhukar H.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (05) : 583 - 591
  • [26] Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Fava, Maurizio
    Durgam, Suresh
    Earley, Willie
    Lu, Kaifeng
    Hayes, Robert
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (06) : 312 - 321
  • [27] The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study
    Quiroz, J. A.
    Tamburri, P.
    Deptula, D.
    Banken, L.
    Beyer, U.
    Fontoura, P.
    Santarelli, L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S468 - S468
  • [28] A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxiine succinate in the treatment of major depressive disorder
    DeMartinis, Nicolas A.
    Yeung, Paul P.
    Entsuah, Richard
    Manley, Amy L.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (05) : 677 - 688
  • [29] Rosemary as an adjunctive treatment in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial
    Azizi, Saeed
    Mohamadi, Neda
    Sharififar, Fariba
    Dehghannoudeh, Gholamreza
    Jahanbakhsh, Farzaneh
    Dabaghzadeh, Fatemeh
    [J]. COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 49
  • [30] Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial
    Khatereh Sepanjnia
    Amirhossein Modabbernia
    Mandana Ashrafi
    Mohammad-Jafar Modabbernia
    Shahin Akhondzadeh
    [J]. Neuropsychopharmacology, 2012, 37 : 2093 - 2100
12345